Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in

  News Archive

OriGene Awarded Contract to Develop Monoclonal Antibodies for SISCAPA
Monday, January 11, 2016
OriGene Technologies have announced that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.

Pfizer, Adaptive Biotechnologies Collaborate
Monday, January 11, 2016
Pfizer Inc. and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise.

Aelix Therapeutics Raises €11.5M for Therapeutic HIV Vaccine
Monday, January 11, 2016
Funds will support proof of concept studies for lead candidate HTI immunogen as a therapeutic vaccine against HIV infection.

Study Shows Blocking Brain Inflammation Could Help Alzheimer's
Saturday, January 09, 2016
The research was jointly funded by the Medical Research Council (MRC) and Alzheimer’s Research UK.

Antibiotics Pave Way for C. Diff Infections
Friday, January 08, 2016
New research from North Carolina State University and the University of Michigan finds that bile acids which are altered by bacteria normally living in the large intestine inhibit the growth of Clostridium difficile,or C. diff. C. diff is a harmful bacterium that can cause painful and sometimes fatal infections.

Takeda Acquires U.S. Biologics Manufacturing Facility
Thursday, January 07, 2016
Takeda Pharmaceutical Company Limited has announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc.

Complix Launches Strategic Collaboration with Merck
Thursday, January 07, 2016
Complix to receive upfront fees, research funding, and milestone payments.

Flu Virus Hijacking Tactics Revealed
Thursday, January 07, 2016
Scientists at Imperial College London have discovered how flu viruses 'hijack' cell machinery when they infect the body.

Preventing HER2+ Breast Cancer Recurrence
Wednesday, January 06, 2016
Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient’s immune system – a weakness that in principle could be corrected with a HER2-targeted vaccine – according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

<< 3 4 5 6 7 8 9 >>
Showing Results 51 - 60 of 1726

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos